{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:14:48Z","timestamp":1795011288794,"version":"4.9.1"},"reference-count":87,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/007\/2016"],"award-info":[{"award-number":["NMRC\/CSA-SI\/007\/2016"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>Discovery and development of clinically useful biomarkers for Alzheimer\u2019s disease (AD) and related dementias have been the focus of recent research efforts. While cerebrospinal fluid and positron emission tomography or MRI-based neuroimaging markers have made the in vivo detection of AD pathology and its consequences possible, the high cost and invasiveness have limited their widespread use in the clinical setting. On the other hand, advances in potentially more accessible blood-based biomarkers had been impeded by lack of sensitivity in detecting changes in markers of the hallmarks of AD, including amyloid-\u03b2 (A\u03b2) peptides and phosphorylated tau (P-tau). More recently, however, emerging technologies with superior sensitivity and specificity for measuring A\u03b2 and P-tau have reported high concordances with AD severity. In this focused review, we describe several emerging technologies, including immunoprecipitation-mass spectrometry (IP-MS), single molecule array and Meso Scale Discovery immunoassay platforms, and appraise the current literature arising from their use to identify plaques, tangles and other AD-associated pathology. While there is potential clinical utility in adopting these technologies, we also highlight the further studies needed to establish A\u03b2 and P-tau as blood-based biomarkers for AD, including validation with existing large sample sets, new independent cohorts from diverse backgrounds as well as population-based longitudinal studies. In conclusion, the availability of sensitive and reliable measurements of A\u03b2 peptides and P-tau species in blood holds promise for the diagnosis, prognosis and outcome assessments in clinical trials for AD.<\/jats:p>","DOI":"10.1136\/jnnp-2021-327370","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T17:20:19Z","timestamp":1631380819000},"page":"1231-1241","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":106,"title":["Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: a focused review on recent advances"],"prefix":"10.1136","volume":"92","author":[{"given":"Joyce R.","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-1424","authenticated-orcid":false,"given":"Mitchell K.P.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,11]]},"reference":[{"key":"2023050404000671000_92.11.1231.1","unstructured":"World Alzheimer Report . The state of the art of dementia research: new frontiers. Alzheimer\u2019s Disease International, 2018."},{"key":"2023050404000671000_92.11.1231.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"2023050404000671000_92.11.1231.3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/bmm-2017-0433","article-title":"Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease","volume":"12","author":"Ashton","year":"2018","journal-title":"Biomark Med"},{"key":"2023050404000671000_92.11.1231.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"2023050404000671000_92.11.1231.5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023050404000671000_92.11.1231.6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.semnuclmed.2020.12.005","article-title":"Advances in brain amyloid imaging","volume":"51","author":"Krishnadas","year":"2021","journal-title":"Semin Nucl Med"},{"key":"2023050404000671000_92.11.1231.7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2023050404000671000_92.11.1231.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2023050404000671000_92.11.1231.9","first-page":"169","article-title":"Plasma biomarkers of AD emerging as essential tools for drug development: an EU\/US CTAD Task force report","volume":"6","author":"Bateman","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"2023050404000671000_92.11.1231.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"2023050404000671000_92.11.1231.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2B proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.13","unstructured":"Swanson CJ ZY , Dhadda S , Wang J . Clinical and biomarker updates from BAN2401 Study 201 in early AD. Clinical Trials on Alzheimer\u2019s Disease Conference: 24\u201327 October 2018; Barcelona."},{"key":"2023050404000671000_92.11.1231.14","doi-asserted-by":"crossref","unstructured":"Swanson C ZY , Dhadda S , Wang J . The GAP study of BAN2401 study 201 in early AD. Persistence of BAN2401-mediated amyloid reductions post-treatment: a preliminary comparison of amyloid status between the core phase of BAN2401-g000-201 and baseline of the open-label extension phase in subjects with early Alzheimer\u2019s disease. Clinical Trials on Alzheimer\u2019s Disease conference: 4\u20137 December 2019; San Diego.","DOI":"10.1212\/WNL.94.15_supplement.1330"},{"key":"2023050404000671000_92.11.1231.15","doi-asserted-by":"crossref","unstructured":"Budd-Haeberlein S VHC , Tian Y , Chalkias S . EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease. Clinical Trials on Alzheimer\u2019s Disease Conference: 4\u20137 December 2019; San Diego.","DOI":"10.1002\/alz.047259"},{"key":"2023050404000671000_92.11.1231.16","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt162"},{"key":"2023050404000671000_92.11.1231.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2008.03.027"},{"key":"2023050404000671000_92.11.1231.18","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801"},{"key":"2023050404000671000_92.11.1231.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07478.x"},{"key":"2023050404000671000_92.11.1231.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07568.x"},{"key":"2023050404000671000_92.11.1231.21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt062"},{"key":"2023050404000671000_92.11.1231.22","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-Precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"2023050404000671000_92.11.1231.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis","volume":"12","author":"De Meyer","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028263"},{"key":"2023050404000671000_92.11.1231.25","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25334"},{"key":"2023050404000671000_92.11.1231.26","doi-asserted-by":"crossref","unstructured":"Thijssen E , Verberk IMW , Vanderstichele HM . O3-09-06: a prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate participants with AD from healthy control subjects. Alzheimer's & Dementia 2018;14:P1039. doi:10.1016\/j.jalz.2018.06.2824","DOI":"10.1016\/j.jalz.2018.06.2824"},{"key":"2023050404000671000_92.11.1231.27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2023050404000671000_92.11.1231.28","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.90.353"},{"key":"2023050404000671000_92.11.1231.29","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2023050404000671000_92.11.1231.30","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"2023050404000671000_92.11.1231.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.06.2266"},{"key":"2023050404000671000_92.11.1231.32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","article-title":"The amyloid-\u03b2 degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease","volume":"573","author":"Pannee","year":"2014","journal-title":"Neurosci Lett"},{"key":"2023050404000671000_92.11.1231.33","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.274"},{"key":"2023050404000671000_92.11.1231.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1932-x"},{"key":"2023050404000671000_92.11.1231.35","doi-asserted-by":"crossref","unstructured":"Palmqvist S , Janelidze S , Stomrud E , et al . Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol 2019;76:e191632. doi:10.1001\/jamaneurol.2019.1632","DOI":"10.1001\/jamaneurol.2019.1632"},{"key":"2023050404000671000_92.11.1231.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.01.013"},{"key":"2023050404000671000_92.11.1231.37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","article-title":"Multiplex immunoassay measurement of amyloid-\u03b2 42 to amyloid-\u03b2 40 ratio in plasma discriminates between dementia due to Alzheimer\u2019s disease and dementia not due to Alzheimer\u2019s disease","volume":"236","author":"Vogelgsang","year":"2018","journal-title":"Exp Brain Res"},{"key":"2023050404000671000_92.11.1231.38","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer's disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2023050404000671000_92.11.1231.39","doi-asserted-by":"publisher","DOI":"10.1021\/cn500101j"},{"key":"2023050404000671000_92.11.1231.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09030-2","article-title":"Subtyping of circulating exosome-bound amyloid \u03b2 reflects brain plaque deposition","volume":"10","author":"Lim","year":"2019","journal-title":"Nat Commun"},{"key":"2023050404000671000_92.11.1231.41","doi-asserted-by":"crossref","unstructured":"Tanaka T et al . Head-To-Head comparison of amplified plasmonic exosome A\u03b242 platform and single-molecule array immunoassay in a memory clinic cohort. Eur J Neurol 2020.","DOI":"10.1111\/ene.14704"},{"key":"2023050404000671000_92.11.1231.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0324-0","article-title":"Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer's disease","volume":"9","author":"Wang","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.43","doi-asserted-by":"crossref","unstructured":"An SSA et al . Dynamic changes of oligomeric amyloid \u03b2 levels in plasma induced by spiked synthetic A\u03b242. Alzheimer\u2019s Res Ther 2017;9:86.","DOI":"10.1186\/s13195-017-0310-6"},{"key":"2023050404000671000_92.11.1231.44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav1388"},{"key":"2023050404000671000_92.11.1231.45","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"2023050404000671000_92.11.1231.46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"2023050404000671000_92.11.1231.47","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy NR , Horie K , Sato C , et al . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 2020;217.doi:10.1084\/jem.20200861","DOI":"10.1084\/jem.20200861"},{"key":"2023050404000671000_92.11.1231.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2023050404000671000_92.11.1231.49","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323487"},{"key":"2023050404000671000_92.11.1231.50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2023050404000671000_92.11.1231.51","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12332","article-title":"Plasma p-Tau181 to A\u03b242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease","author":"Chong","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2023050404000671000_92.11.1231.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1"},{"key":"2023050404000671000_92.11.1231.53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"2023050404000671000_92.11.1231.54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho\u2010tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau\u2010 and amyloid\u2010positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer's & Dementia"},{"key":"2023050404000671000_92.11.1231.55","doi-asserted-by":"crossref","unstructured":"Karikari TK , Benedet AL , Ashton NJ . Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry 2020.doi:10.1038\/s41380-020-00923-z","DOI":"10.1101\/2020.07.15.20154237"},{"key":"2023050404000671000_92.11.1231.56","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab073","article-title":"Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals","volume":"3","author":"Lussier","year":"2021","journal-title":"Brain Commun"},{"key":"2023050404000671000_92.11.1231.57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"key":"2023050404000671000_92.11.1231.58","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00802-x","article-title":"Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer\u2019s disease","volume":"13","author":"Tissot","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/acn3.51253","article-title":"Plasma phosphorylated tau181 and neurodegeneration in Alzheimer\u2019s disease","volume":"8","author":"Hansson","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2023050404000671000_92.11.1231.60","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00805-8","article-title":"Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression","volume":"13","author":"Clark","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.61","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00754-8","article-title":"Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's disease neuroimaging initiative","volume":"13","author":"Zettergren","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.62","doi-asserted-by":"crossref","unstructured":"O\u2019Connor A , Karikari TK , Poole T . Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study. Mol Psychiatry 2020;34.doi:10.1038\/s41380-020-0838-x","DOI":"10.1038\/s41380-020-0838-x"},{"key":"2023050404000671000_92.11.1231.63","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/alz.12236","article-title":"Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis","volume":"17","author":"Karikari","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2023050404000671000_92.11.1231.64","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2023050404000671000_92.11.1231.65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"key":"2023050404000671000_92.11.1231.66","doi-asserted-by":"publisher","DOI":"10.1021\/cn400129p"},{"key":"2023050404000671000_92.11.1231.67","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2023050404000671000_92.11.1231.68","doi-asserted-by":"publisher","DOI":"10.2174\/1568007054546117"},{"key":"2023050404000671000_92.11.1231.69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/joim.12495","article-title":"Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region","volume":"280","author":"Chen","year":"2016","journal-title":"J Intern Med"},{"key":"2023050404000671000_92.11.1231.70","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0206-2"},{"key":"2023050404000671000_92.11.1231.71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90746-x","article-title":"High burden of cerebral white matter lesion in 9 Asian cities","volume":"11","author":"Lam","year":"2021","journal-title":"Sci Rep"},{"key":"2023050404000671000_92.11.1231.72","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2023050404000671000_92.11.1231.73","first-page":"679","article-title":"Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals","volume":"11","author":"Benedet","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2023050404000671000_92.11.1231.74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"key":"2023050404000671000_92.11.1231.75","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","article-title":"Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures","volume":"93","author":"Mielke","year":"2019","journal-title":"Neurology"},{"key":"2023050404000671000_92.11.1231.76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023050404000671000_92.11.1231.77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023050404000671000_92.11.1231.78","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"key":"2023050404000671000_92.11.1231.79","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1093\/brain\/awaa342","article-title":"Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease","volume":"143","author":"Benedet","year":"2020","journal-title":"Brain"},{"key":"2023050404000671000_92.11.1231.80","doi-asserted-by":"crossref","unstructured":"Pereira JB , Janelidze S , Smith R , et al . Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 2021.doi:10.1093\/brain\/awab223","DOI":"10.1093\/brain\/awab223"},{"key":"2023050404000671000_92.11.1231.81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-200755","article-title":"Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage","volume":"78","author":"Asken","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"2023050404000671000_92.11.1231.82","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta(1-42\/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.83","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2023050404000671000_92.11.1231.84","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023050404000671000_92.11.1231.85","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"2023050404000671000_92.11.1231.86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2020.4835","article-title":"The future is P-Tau-Anticipating direct-to-consumer Alzheimer disease blood tests","volume":"78","author":"Largent","year":"2021","journal-title":"JAMA Neurol"},{"key":"2023050404000671000_92.11.1231.87","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-Tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-327370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T06:22:09Z","timestamp":1725776529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-327370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,11]]},"references-count":87,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,10,13]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/jnnp-2021-327370"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-327370","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,11]]}}}